Issue navigation
Volume 31, Issue 1, 2 January 2021
Review Article
Drug Approval Report
Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 1–12, https://doi.org/10.1080/14397595.2020.1812201
Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 13–19, https://doi.org/10.1080/14397595.2020.1826665
Which is the best SLE activity index for clinical trials?
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 20–28, https://doi.org/10.1080/14397595.2020.1775928
Original Article
Special Article
2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 29–33, https://doi.org/10.1080/14397595.2019.1709944
Rheumatoid Arthritis
Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 34–41, https://doi.org/10.1080/14397595.2019.1703484
Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 42–52, https://doi.org/10.1080/14397595.2019.1709681
A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 53–60, https://doi.org/10.1080/14397595.2020.1733214
Efficacy and safety of tacrolimus in patients with rheumatoid arthritis – A systematic review and meta-analysis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 61–69, https://doi.org/10.1080/14397595.2020.1719607
Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 70–79, https://doi.org/10.1080/14397595.2020.1761078
Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 80–87, https://doi.org/10.1080/14397595.2020.1740390
Distinct decrease in peripheral lymphocytes in EBER-positive cases of MTX-LPD
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 88–93, https://doi.org/10.1080/14397595.2020.1733246
Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 94–100, https://doi.org/10.1080/14397595.2020.1741870
Relationship between disease activity of rheumatoid arthritis and development of locomotive syndrome: A five-year longitudinal cohort study
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 101–107, https://doi.org/10.1080/14397595.2020.1744828
Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 108–113, https://doi.org/10.1080/14397595.2020.1743493
Arthrodesis of the digital joint using intraosseous wiring in patients with rheumatoid arthritis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 114–118, https://doi.org/10.1080/14397595.2020.1726607
Renin–angiotensin system molecules are associated with subclinical atherosclerosis and disease activity in rheumatoid arthritis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 119–126, https://doi.org/10.1080/14397595.2020.1740418
Decreased peripheral blood memory B cells are associated with the presence of interstitial lung disease in rheumatoid arthritis: a case-control study
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 127–132, https://doi.org/10.1080/14397595.2020.1719596
Comparative study of HO-1 expressing synovial lining cells between RA and OA
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 133–140, https://doi.org/10.1080/14397595.2019.1704976
Connective Tissues and Related Disorders
Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 141–150, https://doi.org/10.1080/14397595.2020.1751402
The effects of oral treatment for systemic sclerosis related pulmonary arterial hypertension: A systematic review and meta-analysis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 151–161, https://doi.org/10.1080/14397595.2019.1704125
Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 162–170, https://doi.org/10.1080/14397595.2020.1751408
Up-regulation of IGF-1, RANTES and VEGF in patients with anti-centromere antibody-positive early/mild systemic sclerosis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 171–176, https://doi.org/10.1080/14397595.2020.1726599
Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 177–185, https://doi.org/10.1080/14397595.2020.1740400
Human umbilical cord mesenchymal stem cells confer potent immunosuppressive effects in Sjögren’s syndrome by inducing regulatory T cells
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 186–196, https://doi.org/10.1080/14397595.2019.1707996
Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 197–204, https://doi.org/10.1080/14397595.2020.1724671
Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 205–213, https://doi.org/10.1080/14397595.2019.1707997
HLA-A26 is a risk factor for Behçet’s disease ocular lesions
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 214–218, https://doi.org/10.1080/14397595.2019.1705538
Age of onset as an influencing factor for disease severity in children with familial Mediterranean fever
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 219–222, https://doi.org/10.1080/14397595.2020.1719594
The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 223–225, https://doi.org/10.1080/14397595.2019.1709258
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 226–234, https://doi.org/10.1080/14397595.2020.1783163
Phenotyping of IgG4-related diseases based on affected organ pattern: A multicenter cohort study using cluster analysis
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 235–240, https://doi.org/10.1080/14397595.2019.1703522
Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4 in IgG4-related kidney disease
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 241–248, https://doi.org/10.1080/14397595.2019.1709942
Cytotoxic Tph-like cells are involved in persistent tissue damage in IgG4-related disease
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 249–260, https://doi.org/10.1080/14397595.2020.1719576
Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 261–269, https://doi.org/10.1080/14397595.2020.1784556
Uric acid-mediated inflammasome activation in IL-6 primed innate immune cells is regulated by baricitinib
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 270–275, https://doi.org/10.1080/14397595.2020.1740410
Corrigendum
Correction
Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Page 276, https://doi.org/10.1080/14397595.2021.1851033
